Karyopharm Therapeutics | KPTI - Umsatzerlöse

Aktienkurs
8.00
Täglich Wechseln
-0.16 -1.96%
Monatlich
-8.57%
Jährlich
86.48%
Q2 Prognose
7.78




Der Umsatz Veränderung Datum
AbbVie USD 16.62B 840M 2025-12
Abbott USD 11.46B 90M 2025-12
Amgen USD 9.9B 340M 2025-12
AstraZeneca USD 15.5B 313M 2025-12
BioCryst Pharmaceuticals USD 406.56M 247.16M 2025-12
Bristol-Myers Squibb USD 12.5B 300M 2025-12
Eli Lilly USD 19.3B 1.7B 2025-12
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
GlaxoSmithKline GBP 8.62B 73M 2025-12
Incyte USD 1.51B 140M 2025-12
J&J USD 24.6B 610M 2025-12
Karyopharm Therapeutics USD 34.08M 3.54M 2025-12
MacroGenics USD 41.23M 31.61M 2025-12
Merck USD 16.4B 880M 2025-12
Nektar Therapeutics USD 21.81M 2.32M 2025-12
Novartis USD 13.86B 50M 2025-12
Novartis USD 13.86B 498M 2025-12
Pfizer USD 17.58B 880M 2025-12
Regeneron Pharmaceuticals USD 3.88B 130M 2025-12
Roche Holding CHF 15.65B 274.5M 2025-12
Sangamo BioSciences USD 356K 125K 2024-06
Takeda JPY 1.19T 80B 2025-12
Tectonic Therapeutic USD 0 0 2024-12
TG Therapeutics USD 192.57M 30.87M 2025-12
Ultragenyx Pharmaceutical USD 207M 47M 2025-12
Xencor USD 28.24M 7.24M 2025-12